Sumatriptan (subcutaneous route of administration) for acute migraine attacks in adults

Cochrane Database of Systematic Reviews

Volumn 2017, Issue 10, 2012, Pages

  Derry, Christopher J ^a   Derry, Sheena ^a   Moore, R Andrew ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; DIHYDROERGOTAMINE; METOCLOPRAMIDE; PLACEBO; SUMATRIPTAN; TRIPTAN DERIVATIVE; SEROTONIN 1 AGONIST;

ACUTE MIGRAINE; ADULT; ANALGESIA; ASTHENIA; BACKACHE; CHEST TIGHTNESS; COMPARATIVE EFFECTIVENESS; DISEASE ASSOCIATION; DISEASE SEVERITY; DIZZINESS; DROWSINESS; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FUNCTIONAL DISEASE; HEADACHE; HOT FLUSH; HUMAN; INJECTION SITE REACTION; MALAISE; MIGRAINE; MOUTH DISEASE; NAUSEA; NECK PAIN; OUTCOME ASSESSMENT; PARESTHESIA; PHOTOPHOBIA; PRIORITY JOURNAL; PUBLICATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK BENEFIT ANALYSIS; RISK FACTOR; SIDE EFFECT; SOMNOLENCE; SWEAT GLAND DISEASE; SYSTEMATIC REVIEW; TASTE DISORDER; THORAX PAIN; THROAT DISEASE; VERTIGO; VOMITING; ACUTE DISEASE; META ANALYSIS; METHODOLOGY; SUBCUTANEOUS DRUG ADMINISTRATION; TIME;

ACUTE DISEASE; ADULT; HUMANS; INJECTIONS, SUBCUTANEOUS; MIGRAINE DISORDERS; PAIN MANAGEMENT; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SEROTONIN 5-HT1 RECEPTOR AGONISTS; SUMATRIPTAN; TIME FACTORS;

EID: 84861309944     PISSN: 14651858     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD009665     Document Type: Review

References (91)

1. Akpunonu BE, Mutgi AB, Federman DJ, Volinsky FG, Brickman K, Davis RL, et al. Subcutaneous sumatriptan for treatment of acute migraine in patients admitted to the emergency department: a multicenter study. Annals of Emergency Medicine 1995;25(4):464-9. 3266451
2. Bates D, Ashford E, Dawson R, Ensink FB, Gilhus NE, Olesen J, et al. Sumatriptan Aura Study Group. Subcutaneous sumatriptan during the migraine aura. Neurology 1994;44(9):1587-92. 3266453
3. Bousser MG, D'Allens H, Richard A. Efficacy of subcutaneous sumatriptan in the acute treatment of early-morning migraine: a placebo-controlled trial. Journal of Internal Medicine 1993;234(2):211-6. 3266455
4. Cady RK, Wendt JK, Kirchner JR, Sargent JD, Rothrock JF, Skaggs H Jr. Treatment of acute migraine with subcutaneous sumatriptan. JAMA 1991;265(21):2831-5. 3266457
5. Repeat-dose efficacy and laboratory safety trial of subcutaneous GR43175C in migraine patients. http://www.gsk-clinicalstudyregister.com/. 3266460
6. Cady RK, Dexter J, Sargent JD, Markley H, Osterhaus JT, Webster CJ. Efficacy of subcutaneous sumatriptan in repeated episodes of migraine. Neurology 1993;43(7):1363-8. 3266459
7. Cady RC, Ryan R, Jhingran P, O'Quinn S, Pait DG. Sumatriptan injection reduces productivity loss during a migraine attack: results of a double-blind, placebo-controlled trial. Archives of Internal Medicine 1998;158(9):1013-8. 3266462
8. Dahlof C, Edwards C, Toth A. Sumatriptan injection is superior to placebo in the acute treatment of migraine--with regard to both efficacy and general well-being. Cephalalgia 1992;12(4):214-20. 3266464
9. Dahlof C, Hogenhuis L, Olesen J, Petit H, Ribbat J, Schoenen J, et al. Early clinical experience with subcutaneous naratriptan in the acute treatment of migraine: a dose-ranging study. European Journal of Neurology 1998;5(5):469-77. [DOI: 10.1046/j.1468-1331.1998.550469.x]3266466
10. Diener HC. Efficacy and safety of intravenous acetylsalicylic acid lysinate compared to subcutaneous sumatriptan and parenteral placebo in the acute treatment of migraine. A double-blind, double-dummy, randomized, multicenter, parallel group study. Cephalalgia 1999;19(6):581-8. 3266468
11. Diener HC, Tfelt-Hansen P, de Beukelaar F, Ferrari MD, Olesen J, Dahlof C, et al. The efficacy and safety of sc alniditan vs. sc sumatriptan in the acute treatment of migraine: a randomized, double-blind, placebo-controlled trial. Cephalalgia 2001;21(6):672-9. [DOI: 11531899]3266470
12. Facchinetti F, Bonellie G, Kangasniemi P, Pascual J, Shuaib A, The Sumatriptan Menstrual Migraine Study Group. The efficacy and safety of subcutaneous sumatriptan in the acute treatment of menstrual migraine. Journal of Obstetrics and Gynecology 1995;86(6):911-6. [PUBMED: 7501338]3266472
13. The Subcutaneous Sumatriptan International Study Group. Treatment of migraine attacks with sumatriptan. New England Journal of Medicine 1991;325(5):316-21. 3266474
14. Gross ML, Kay J, Turner AM, Hallett K, Cleal AL, Hassani H, United Kingdom Study Group. Sumatriptan in acute migraine using a novel cartridge system self-injector. Headache 1994;34(10):559-63. [PUBMED: 9843948]3266476
15. Henry P, d'Allens H, French Migraine Network Bordeaux-Lyon-Grenoble. Subcutaneous sumatriptan in the acute treatment of migraine in patients using dihydroergotamine as prophylaxis. Headache 1993;33(8):432-5. 3266478
16. Jensen K, Tfelt-Hansen P, Hansen EW, Krøis EH, Pedersen OS. Introduction of a novel self-injector for sumatriptan. A controlled clinical trial in general practice. Cephalalgia 1995;15(5):423-9. 3266480
17. Mathew NT, Dexter J, Couch J, Flamenbaum W, Goldstein J, Rapoport A, et al. US Sumatriptan Research Group. Dose ranging efficacy and safety of subcutaneous sumatriptan in the acute treatment of migraine. Archives of Neurology 1992;49(12):1271-6. 3266482
18. Mushet GR, Cady RK, Baker CC, Clements B, Gutterman DL, Davis R. Efficacy and tolerability of subcutaneous sumatriptan administered using the IMITREX STATdose System. Clinical Therapeutics 1996;18(4):687-99. 3266484
19. The Sumatriptan Auto-Injector Study Group. Self-treatment of acute migraine with subcutaneous sumatriptan using an auto-injector device. European Neurology 1991;31(5):323-31. 3266486
20. Russell MB, Holm-Thomsen OE, Rishøj Nielsen M, Cleal A, Pilgrim AJ, Olesen J. A randomized double-blind placebo-controlled crossover study of subcutaneous sumatriptan in general practice. Cephalalgia 1994;14(4):291-6. 3266488
21. A randomised, multicentre, double-blind, double-dummy, parallel-group study to compare the efficacy and safety of subcutaneous sumatriptan with oral aspirin plus oral metoclopramide in the acute treatment of migraine. http://www.gsk-clinicalstudyregister.com/. 3266490
22. A double-blind, randomised, placebo controlled, crossover study to assess return of headache in patients treated with 6 mg subcutaneous sumatriptan early or late in a migraine attack; with optional open-label doses to assess pattern of use of sumatriptan over the subsequent 72 hour period. http://www.gsk-clinicalstudyregister.com/. 3266492
23. A double-blind, placebo-controlled, parallel group study of 6 mg subcutaneous sumatriptan + optional 6 mg subcutaneous sumatriptan administered using a novel cartridge system self-injector in slow developing migraine. http://www.gsk-clinicalstudyregister.com/. 3266494
24. Sang CN, Ramadan NM, Wallihan RG, Chappell AS, Freitag FG, Smith TR, et al. LY293558, a novel AMPA/GluR5 antagonist, is efficacious and well-tolerated in acute migraine. Cephalalgia 2004;24(7):596-602. 3266496
25. Schulman EA, Cady RK, Henry D, Batenhorst AS, Putnam DG, Watson CB, et al. Effectiveness of sumatriptan in reducing productivity loss due to migraine: results of a randomized, double-blind, placebo-controlled clinical trial. Mayo Clinic Proceedings 2000;75(8):782-9. 3266498
26. A randomized, double-blind, placebo-controlled, parallel-group, single-attack study of sumatriptan 6 mg injection in the treatment of moderate-to-severe migraine present upon awakening. http://www.gsk-clinicalstudyregister.com/. 3266500
27. Winner P, Adelman J, Aurora S, Ames M, Lener M. Pain-free results of sumatriptan 6 mg SC in the treatment or morning migraine: results from two prospective, randomized, double-blind, placebo-controlled studies. Headache 2003;43(5):535. 3266501
28. A randomized, double-blind, placebo-controlled, parallel-group, single-attack study of sumatriptan 6 mg injection in the treatment of moderate-to-severe migraine present upon awakening. http://www.gsk-clinicalstudyregister.com/. 3266503
29. Winner P, Adelman J, Aurora S, Ames M, Lener M. Pain-free results of sumatriptan 6 mg SC in the treatment or morning migraine: results from two prospective, randomized, double-blind, placebo-controlled studies. Headache 2003;43(5):535. 3266504
30. Thomson AN, Arthur GP, Bergin PS, Pollock M, Parkin PJ, Flanagan M, et al. Subcutaneous sumatriptan in acute treatment of migraine: a multicentre New Zealand trial. New Zealand Medical Journal 1993;106(955):171-3. 3266506
31. Touchon J, Bertin L, Pilgrim AJ, Ashford E, Bès A. A comparison of subcutaneous sumatriptan and dihydroergotamine nasal spray in the acute treatment of migraine. Neurology 1996;47(2):361-5. 3266508
32. Visser WH, Ferrari MD, Bayliss EM, Ludlow S, Pilgrim AJ, The Subcutaneous Sumatriptan International Study Group. Treatment of migraine attacks with subcutaneous sumatriptan: first placebo-controlled study. Cephalalgia 1992;12(5):308-13. 3266510
33. Wendt J, Cady R, Singer R, Peters K, Webster C, Kori S, et al. A randomized, double-blind, placebo-controlled trial of the efficacy and tolerability of a 4-mg dose of subcutaneous sumatriptan for the treatment of acute migraine attacks in adults. Clinical Therapeutics 2006;28(4):517-26. [DOI: 10.1016/j.clinthera.2006.03.013]3266512
34. Winner P, Mannix LK, Putnam DG, McNeal S, Kwong J, O'Quinn S, et al. Pain-free results with sumatriptan taken at the first sign of migraine pain: 2 randomized, double-blind, placebo-controlled studies. Mayo Clinic Proceedings 2003 ;78(10):1214-22. [DOI: 10.4065/78.10.1214]3266514
35. Winner P, Adelman J, Aurora S, Lener ME, Ames M. Efficacy and tolerability of sumatriptan injection for the treatment of morning migraine: two multicenter, prospective, randomized, double-blind, controlled studies in adults. Clinical Therapeutics 2006;28(10):1582-91. 3266516
36. Burke-Ramirez P, Asgharnejad M, Webster C, Davis R, Laurenza A. Efficacy and tolerability of subcutaneous sumatriptan for acute migraine: a comparison between ethnic groups. Headache 2001;41(9):873-82. [DOI: 10.1111/j.1526-4610.2001.01159.x]3266518
37. Cady RK, Rubino J, Crummett D, Littlejohn TW 3rd. Oral sumatriptan in the treatment of recurrent headache. Archives of Family Medicine 1994;3(9):766-72. 3266520
38. Cull RE, Price WH, Dunbar A. The efficacy of subcutaneous sumatriptan in the treatment of recurrence of migraine headache. Journal of Neurology, Neurosurgery, and Psychiatry 1997;62(5):490-5. 3266522
39. Ensink FB. Subcutaneous sumatriptan in the acute treatment of migraine. Sumatriptan International Study Group. Journal of Neurology 1991;238 Suppl 1:S66-9. 3266524
40. Friedman BW, Corbo J, Lipton RB, Bijur PE, Esses D, Solorzano C, et al. A trial of metoclopramide vs sumatriptan for the emergency department treatment of migraines. Neurology 2005;64(3):463-8. 3266526
41. Friedman BW, Hochberg M, Esses D, Bijur PE, Corbo J, Paternoster J, et al. A clinical trial of trimethobenzamide/diphenhydramine versus sumatriptan for acute migraines. Headache 2006;46(6):934-41. [DOI: 10.1111/j.1526-4610.2006.00467.x]3266528
42. González-Espinosa LE, Gómez-Viera N, Olivera-Leal I, Reyes-Lorente R. Treatment of acute attack of migraine with sumatriptan [Spanish]. Revista de Neurologia 1997;147:1672-5. 3266530
43. Melchart D, Thormaehlen J, Hager S, Liao J, Linde K, Weidenhammer W. Acupuncture versus placebo versus sumatriptan for early treatment of migraine attacks: a randomized controlled trial. Journal of Internal Medicine 2003;253(2):181-8. [DOI: 10.1046/j.1365-2796.2003.01081.x]3266532
44. Pradel FG, Subedi P, Varghese AA, Mullins CD, Weis KA. Does earlier headache response equate to earlier return to functioning in patients suffering from migraine?. Cephalalgia 2006;26(4):428-35. 3266534
45. Russell MB, Holm-Thomsen OE, Nielsen MR, Cleal A, Pilgrim AJ, Olesen J. Sumatriptan treatment of migraine in general practice. A randomized, double-blind, placebo-controlled cross-over study [Sumatriptan ved migraene i almen praksis. En randomiseret, dobbeltblind, placebokontrolleret overkrydsningsundersogelse]. Ugeskrift for Laeger 1995;157(16):2320-3. 3266536
46. A double-blind, placebo-controlled, parallel group study to evaluate the efficacy, safety and tolerability of a 6 mg SC dose of sumatriptan in patients who have not responded to acute treatment of a migraine attack with 100 mg oral dose of sumatriptan. http://www.gsk-clinicalstudyregister.com/. 3266538
47. Solbach MP, Waymer RS. Treatment of menstruation-associated migraine headache with subcutaneous sumatriptan. Journal of Obstetrics and Gynecology 1993;82(5):769-72. 3266540
48. Bigal ME, Serrano D, Reed M, Lipton RB. Chronic migraine in the population: burden, diagnosis, and satisfaction with treatment. Neurology 2008;71(8):559-66. [DOI: 10.1212/01.wn1.0000323925.29520.e7]
49. Clarke CE, MacMillan L, Sondhi S, Wells NEJ. Economic and social impact of migraine. Quarterly Journal of Medicine 1996;89(1):77-84.
50. Cook RJ, Sackett DL. The number needed to treat: a clinically useful measure of treatment effect. BMJ 1995;310(6977):452-4.
51. Derry CJ, Derry S, Moore RA. Sumatriptan (all routes of administration) for acute migraine attacks in adults: an overview of Cochrane reviews. Cochrane Database of Systematic Reviews (forthcoming).
52. Derry CJ, Derry S, Moore RA. Sumatriptan (oral route of administration) for acute migraine attacks in adults. Cochrane Database of Systematic Reviews 2012, Issue 2. [DOI: 10.1002/14651858.CD008615]
53. Derry CJ, Derry S, Moore RA. Sumatriptan (subcutaneous route of administration) for acute migraine attacks in adults. Cochrane Database of Systematic Reviews 2012, Issue 2. [DOI: 10.1002/14651858.CD009665]
54. Derry CJ, Derry S, Moore RA. Sumatriptan (intranasal route of administration) for acute migraine attacks in adults. Cochrane Database of Systematic Reviews 2012, Issue 2. [DOI: 10.1002/14651858.CD009663]
55. Derry CJ, Derry S, Moore RA. Sumatriptan (rectal route of administration) for acute migraine attacks in adults. Cochrane Database of Systematic Reviews 2012, Issue 2. [DOI: 10.1002/14651858.CD009664]
56. Diamond S, Bigal ME, Silberstein S, Loder E, Reed M, Lipton RB. Patterns of diagnosis and acute and preventive treatment for migraine in the United States: results from the American Migraine Prevalence and Prevention study. Headache 2007;47(3):355-63. [DOI: 10.1111/j.1526-4610.2006.00631.x]
57. Edmeads J, Findlay H, Tugwell P, Pryse-Phillips W, Nelson RF, Murray TJ. Impact of migraine and tension-type headache on life-style, consulting behaviour, and medication use: a Canadian population survey. Canadian Journal of Neurological Sciences 1993;20(2):131-7.
58. Ferrari MD. The economic burden of migraine to society. Pharmacoeconomics 1998;13(6):667-76.
59. Ferrari MD, Goadsby PJ, Roon KI, Lipton RB. Triptans (serotonin, 5-HT1B/1D agonists) in migraine: detailed results and methods of a meta-analysis of 53 trials. Cephalalgia 2002;22(8):633-58. [DOI: 10.1046/j.1468-2982.2002.00404.x]
60. Gawel MJ, Worthington I, Maggisano A. A systematic review of the use of triptans in acute migraine. Canadian Journal of Neurological Sciences 2001;28(1):30-41.
61. Gendolla A. Early treatment in migraine: how strong is the current evidence?. Cephalalgia 2008;28 Suppl 2:28-35.
62. Goadsby PJ. Recent advances in understanding migraine mechanisms, molecules and therapeutics. Trends in Molecular Medicine 2007;13(1):39-44. [DOI: 10.1016/j.molmed.2006.11.005]
63. Hazard E, Munakata J, Bigal ME, Rupnow MF, Lipton RB. The burden of migraine in the United States: current and emerging perspectives on disease management and economic analysis. Value in Health 2009;12(1):55-64. [DOI: 10.1111/j.1524-4733.2008.00404.x]
64. Hu XH, Markson LE, Lipton RB, Stewart WF, Berger ML. Burden of migraine in the United States: disability and economic costs. Archives of Internal Medicine 1999;159(8):813-8.
65. Headache Classification Committee of the International Headache Society. Classification and diagnostic criteria for headache disorders, cranial neuralgias and facial pain. Cephalalgia 1988;8 Suppl 7:1-96.
66. International Headache Society Clinical Trials Subcommittee. Guidelines for controlled trials of drugs in migraine: second edition. Cephalalgia 2000;20(9):765-86.
67. Headache Classification Subcommittee of the International Headache Society. The International Classification of Headache Disorders: 2nd edition. Cephalalgia 2004;24 Suppl 1:1-160.
68. Jadad AR, Carroll D, Moore A, McQuay H. Developing a database of published reports of randomised clinical trials in pain research. 1996 1996;66(2-3):239-46.
69. Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJM, Gavaghan DJ, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary?. Controlled Clinical Trials 1996;17(1):1-12.
70. Jhingran P, Cady RK, Rubino J, Miller D, Grice RB, Gutterman DL. Improvements in health-related quality of life with sumatriptan treatment for migraine. Journal of Family Practice 1996;42(1):36-42.
71. L'Abbé KA, Detsky AS, O'Rourke K. Meta-analysis in clinical research. Annals of Internal Medicine 1987;107(2):224-33.
72. Lipton RB, Stewart WF. Acute migraine therapy: do doctors understand what patients with migraine want from therapy?. Headache 1999;39 Suppl 2:S20-S26.
73. Lipton RB, Bigal ME, Diamond M, Freitag F, Reed ML, AMPP Advisory Group, et al. Migraine prevalence, disease burden, and the need for preventive therapy. Neurology 2007;68(5):343-9.
74. Lofland JH, Johnson NE, Batenhorst AS, Nash DB. Changes in resource use and outcomes for patients with migraine treated with sumatriptan: a managed care perspective. Archives of Internal Medicine 1999;159(8):857-63.
75. Lucas C, Géraud G, Valade D, Chautard MH, Lantéri-Minet M. Recognition and therapeutic management of migraine in 2004, in France: results of FRAMIG 3, a French nationwide population-based survey. Headache 2006;46(5):715-25. [DOI: 10.1111/j.1526-4610.2006.00430.x]
76. McCrory DC, Gray RN. Oral sumatriptan for acute migraine. Cochrane Database of Systematic Reviews 2003, Issue 3. [DOI: 10.1002/14651858.CD002915]
77. Moore RA, Gavaghan D, Tramèr MR, Collins SL, McQuay HJ. Size is everything - large amounts of information are needed to overcome random effects in estimating direction and magnitude of treatment effects. Pain 1998;78(3):209-16.
78. Moore RA, Barden J, Derry S, McQuay HJ. Managing potential publication bias. In: McQuay HJ, Kalso E, Moore RA editor(s). Systematic Reviews in Pain Research: Methodology Refined. Seattle: IASP Press, 2008:15-24.
79. Moore RA, Eccleston C, Derry S, Wiffen P, Bell RF, Straube S, et al. ''Evidence" in chronic pain - establishing best practice in the reporting of systematic reviews. Pain 2010;150(3):386-9.
80. Morris JA, Gardner MJ. Calculating confidence intervals for relative risk, odds ratios and standardised ratios and rates. In: Gardner MJ, Altman DG editor(s). Statistics with Confidence - Confidence Intervals and Statistical Guidelines. London: British Medical Journal, 1995:50-63.
81. Oldman AD, Smith LA, McQuay HJ, Moore RA. Pharmacological treatments for acute migraine: quantitative systematic review. Pain 2002;97(3):247-57.
82. Osterhaus JT, Townsend RJ, Gandek B, Ware JE Jr. Measuring the functional status and well-being of patients with migraine headache. Headache 1994;34(6):337-43.
83. Pascual J. Clinical benefits of early triptan therapy for migraine. Headache 2002;42 Suppl 1:10-7. [DOI: 10.1046/j.1526-4610.2002.0420s1010.x]
84. Anonymous. Prescription cost analysis, England 2010. The NHS Information Centre, Prescribing Support Unit 2011. [ISBN: 978-1-84636-542-3]
85. Radtke A, Neuhauser H. Prevalence and burden of headache and migraine in Germany. Headache 2009;49(1):79-89. [DOI: 10.1111/j.1526-4610.2008.01263.x]
86. The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.1. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2011.
87. Solomon GD, Price KL. Burden of migraine. A review of its socioeconomic impact. Pharmacoeconomics 1997;11 Suppl 1:1-10.
88. Stovner LJ, Andree C. Prevalence of headache in Europe: a review for the Eurolight project. Journal of Headache and Pain 2010;11(4):289-99. [DOI: 10.1007/s10194-010-0217-0]
89. Tfelt-Hansen P. Efficacy and adverse events of subcutaneous, oral, and intranasal sumatriptan used for migraine treatment: a systematic review based on number needed to treat. Cephalalgia 1998;18(8):532-8.
90. Tramèr MR, Reynolds DJM, Moore RA, McQuay HJ. Impact of covert duplicate results on meta-analysis: a case study. BMJ 1997;315(7109):635-40.
91. Victor TW, Hu X, Campbell JC, Buse DC, Lipton RB. Migraine prevalence by age and sex in the United States: a life-span study. Cephalalgia 2010;30(9):1065-72. [DOI: 10.1177/0333102409355601]